Inventor · disambiguated record
Jeffrey T. Mcgrew
Also filed as: MCGREW JEFFREY T
19 granted patents·4 pending applications·469 citations·filing 1995–2023
95Inventor score
Top patents by PatentIndex Score
23 records- 0195US6974681B1Cell culture performance with vanadateIMMUNEX CORP·Filed 2002·Granted Dec 13, 2005·63 cites·38 claims
- 0294US5962406ARecombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the sameIMMUNEX CORP·Filed 1995·Granted Oct 5, 1999·96 cites·71 claims
- 0393US6872549B2Methods for increasing polypeptide productionIMMUNEX CORP·Filed 2003·Granted Mar 29, 2005·71 cites·69 claims
- 0491US6632637B1Vectors and methods for recombinant protein expressionIMMUNEX CORP·Filed 2000·Granted Oct 14, 2003·26 cites·44 claims
- 0591US6410711B1DNA encoding CD40 ligand, a cytokine that binds CD40IMMUNEX CORP·Filed 1999·Granted Jun 25, 2002·64 cites·68 claims
- 0689US11098310B2Expression from transposon-based vectors and usesJUST EVOTEC BIOLOGICS INC·Filed 2019·Granted Aug 24, 2021·5 cites·13 claims
- 0788US11685933B2Inducible expression from transposon-based vectors and usesJUST EVOTEC BIOLOGICS INC·Filed 2022·Granted Jun 27, 2023·1 cites·13 claims
- 0888US11028410B2Hybrid promoter and uses thereofJUST EVOTEC BIOLOGICS INC·Filed 2017·Granted Jun 8, 2021·6 cites·29 claims
- 0988US5981724ADNA encoding CD40 ligand, a cytokine that binds CD40IMMUNEX CORP·Filed 1995·Granted Nov 9, 1999·65 cites·188 claims
- 1087US11261462B2Inducible expression from transposon-based vectors and usesJUST EVOTEC BIOLOGICS INC·Filed 2019·Granted Mar 1, 2022·4 cites·13 claims
- 1185US11692193B2Expression from transposon-based vectors and usesJUST EVOTEC BIOLOGICS INC·Filed 2021·Granted Jul 4, 2023·1 cites·13 claims
- 1285US7452695B2Methods for increasing polypeptide productionIMMUNEX CORP·Filed 2005·Granted Nov 18, 2008·7 cites·27 claims
- 1379US11384140B2Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectorsAMGEN INC·Filed 2017·Granted Jul 12, 2022·2 cites·21 claims
- 1479US6291661B1flt3-L mutants and method of useIMMUNEX CORP·Filed 1998·Granted Sep 18, 2001·47 cites·29 claims
- 1577US7067118B2Methods of using mutant flt3-ligand polypeptides to induce cellular expansionIMMUNEX CORP·Filed 2001·Granted Jun 27, 2006·6 cites·54 claims
- 1674US8257707B2IL-18 receptor antigen binding proteinsSMITH DIRK E·Filed 2008·Granted Sep 4, 2012·2 cites·21 claims
- 1773US7691605B2Selection of cells expressing heteromeric polypeptidesIMMUNEX CORP·Filed 2002·Granted Apr 6, 2010·3 cites·36 claims
- 1869US2024035037A1Transposon-based vectors and usesJUST EVOTEC BIOLOGICS INC·Filed 2023·Application pending·0 cites
- 1966US7968313B2Selection of cells expressing heteromeric polypeptidesIMMUNEX CORP·Filed 2009·Granted Jun 28, 2011·0 cites·26 claims
- 2059US2004063186A1Vectors and methods for recombinant protein expressionIMMUNEX CORP·Filed 2003·Application pending·0 cites
- 2155US2014093915A1Il-18 receptor antigen binding proteinsAMGEN INC·Filed 2013·Application pending·0 cites
- 2255US2007031422A1Selection of cells expressing heteromeric polypeptidesIMMUNEX CORP·Filed 2006·Application pending·0 cites
- 2354US8540993B2Methods of treatment using IL-18 receptor antigen binding proteinsSMITH DIRK E·Filed 2012·Granted Sep 24, 2013·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Jeffrey T. Mcgrew files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →